Results 141 to 150 of about 843,559 (297)

The efficacy of concurrent chemoradiotherapy with or without nimotuzumab in high‐risk patients with locally advanced head and neck squamous cell carcinoma post‐surgery: A real‐world study

open access: yesPrecision Radiation Oncology, EarlyView.
Figure 1 Patient selection flowchart. CCRT, concurrent chemoradiotherapy; NCCRT, nimotuzumab and concurrent chemoradiotherapy. Abstract Purpose Patients with locally advanced head and neck squamous cell carcinoma (LA‐HNSCC) harboring high‐risk pathological features after radical surgery face high recurrence rates.
Yuejia Zhou   +8 more
wiley   +1 more source

Humanized Anti-Trop-2 Monocolonal Antibodies and Uses Thereof

open access: yes, 2014
The present invention relates to humanized anti-Trop-5 2 monoclonal antibodies and their fragments, derivatives and conjugates. In particular the present invention relates to monoclonal antibodies consisting of sequences of human and murine mixed ...
Alberti Saverio, Emanuela Guerra
core  

Mirikizumab pharmacokinetics and exposure–response in pediatric patients with moderate‐to‐severe ulcerative colitis

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 474-485, March 2025.
Abstract Mirikizumab is a p19‐directed anti‐interleukin‐23 antibody approved for the treatment of adults with moderate‐to‐severe ulcerative colitis (UC). Here, we report the first data of mirikizumab pharmacokinetics (PK) and exposure–response (E/R) relationships in pediatric participants (aged 2 to <18 years weighing >10 kg) with moderate‐to‐severe UC
Yuki Otani   +5 more
wiley   +1 more source

HER2‐Targeted AIE Nanotheranostics Overcome SHR‐A1811 Resistance via Immunogenic Pyroptosis and Tumor‐Associated Macrophage Reprogramming in Breast Cancer

open access: yesSmall, EarlyView.
HER2‐targeted AIE780‐A1811 nanoparticles self‐assemble via amide coupling of a mitochondria‐directed photosensitizer with the ADC SHR‐A1811. Upon 660 nm irradiation, they generate ROS, photothermal effects, and controlled drug release, inducing immunogenic pyroptosis and M2‐to‐M1 macrophage reprogramming. This dual action remodels the immunosuppressive
Xiaohong Liu   +12 more
wiley   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

open access: yesSmart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou   +4 more
wiley   +1 more source

The Utility of Intranasal Corticosteroids in Association With Dupilumab for Chronic Rhinosinusitis With Nasal Polyposis: A Real‐Life Multicenter Study by a Tuscany Group

open access: yesWorld Journal of Otorhinolaryngology - Head and Neck Surgery, EarlyView.
ABSTRACT Objective Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition often associated with other type‐2 diseases. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has revolutionized the treatment of severe CRSwNP.
Pietro Orlando   +17 more
wiley   +1 more source

Effectiveness and Safety of Vunakizumab Over 12 Weeks in Chinese Patients With Plaque Psoriasis: A Prospective, Real‐World Cohort Study

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Vunakizumab is a humanized anti‐IL‐17A monoclonal antibody approved in China for moderate‐to‐severe plaque psoriasis. Real‐world data on its effectiveness and predictors of response remain scarce. This prospective, single‐center, observational study enrolled 34 adults receiving vunakizumab (240 mg subcutaneously at weeks 0, 2, and 4, then ...
Tong Wu   +4 more
wiley   +1 more source

Rademikibart for Asthma With Type 2 Biomarkers: Exploratory Subgroup Analyses From a Phase 2b Randomized Clinical Trial

open access: yesAllergy, EarlyView.
This study reports exploratory and predominantly post hoc subgroup analyses, according to baseline eosinophil count and FeNO levels. In adults with moderate‐to‐severe uncontrolled asthma, rademikibart produced rapid and sustained improvements in lung function and asthma control.
Michael E. Wechsler   +3 more
wiley   +1 more source

Meta‐Analysis: Safety and Effectiveness of Advanced Therapies in Inflammatory Bowel Disease Patients With Concomitant Primary Sclerosing Cholangitis

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
Advanced IBD therapies appear safe and effective in PSC‐IBD. However remission and response rates appear numerically attenuated compared to IBD‐only populations. Created in BioRender (https://BioRender.com/h9bxgij). ABSTRACT Background Inflammatory bowel disease (IBD) associated with primary sclerosing cholangitis (PSC) is a distinct phenotype (PSC‐IBD)
Amera Elzubeir   +6 more
wiley   +1 more source

Protective role of Galectin‐3 in prion disease through regulation of microglial PrPSc uptake

open access: yesBrain Pathology, EarlyView.
Galectin‐3 (Gal3) is induced in reactive microglia during prion disease and promotes microglial uptake of PrPSc. Gal3 deficiency reduces prion sequestration and accelerates disease progression, revealing a protective role for Gal3. Abstract Microglia constitute a major innate defense mechanism against prion infection; however, the molecular pathways ...
Natallia Makarava   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy